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Background: A meta-analysis was performed to evaluate the risk of major bleeding with the use 
of New Oral Anticoagulants (NOACs). 
Methods: Randomized controlled trials (RCTs) comparing NOACs (rivaroxaban, dabigatran, 
apixaban, edoxaban and darexaban) with comparators were selected.   
Results: Fifty trials included 155,537 patients. Pooled analysis of all NOACs for all indications 
together demonstrated no significant difference between NOACs and comparators for risk of 
major bleeding (Odds Ratio [OR] 0.93, 95% CI 0.79- 1.09). Pooled analysis also showed, 
NOACs caused significantly less major bleeding compared to vitamin K antagonists (VKA) 
(0.77, 0.64- 0.91). Analysis for individual NOACs showed risk of major bleeding were not 
different with rivaroxaban, apixaban or dabigatran compared to pharmacologically active 
comparators or VKA. Indication specific analysis showed, NOACs were associated with 
significantly higher major bleeding after hip surgery (1.43, 1.02 -1.99), in patients with acute 
coronary syndrome (ACS), (compared against placebo) (2.89, 2.01-4.14), and for medically ill 
patients (2.79, 1.69-4.60). For the treatment of acute venous thromboembolism (VTE) or 
pulmonary embolism (PE), NOACs were associated with significantly less bleeding (0.63, 0.44-
0.90). No significant difference was found between NOACs and comparators in treatment of 
atrial fibrillation and for extended treatment of VTE. 
Conclusions: Risk of major bleeding with new oral anticoagulants varies with their indication 
for use. New agents may be associated with comparatively less major bleeding compared to 
VKA. NOAC may increase the risk of major bleeding after hip surgery, ACS and acute 
medically ill patients; but may be associated with less bleeding in treatment of acute VTE/PE. 
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Introduction   
 
New oral anticoagulant agents (NOACs) have been developed in recent years for use in different 
indications. The newer agents have specific advantages over conventional anticoagulants, 
including rapid onset of action, predictable therapeutic effect, and limited interactions with other 
drugs (1).  The two groups of NOACs include the factor Xa (FXa) inhibitors (eg. rivaroxaban, 
apixaban, edoxaban and darexaban) and direct thrombin inhibitors (DTIs, eg. dabigatran and 
ximelagatran) (1).  
Rivaroxaban is approved in the United States and Europe for thromboprophylaxis after 
orthopedic surgery, treatment of venous thromboembolism (VTE), and for stroke prevention in 
patients with atrial fibrillation (AF); in Europe rivaroxaban has been recently approved for acute 
coronary syndrome (ACS) (1-4). Apixaban is approved in Europe for patients with atrial 
fibrillation and for thromboprophylaxis after orthopedic surgery and  in the United States 
apixaban recently received approval for patients with atrial fibrillation only (5, 6). Ximelagatran 
is no longer available because of reports of liver toxicity (1). Dabigatran is approved in the 
United States for stroke prevention in non-valvular AF, and in Europe this drug received 
additional approval for thromboprophylaxis after orthopedic surgery (1, 7, 8). Other new drugs, 
edoxaban and darexaban have been evaluated in phase II trials (1,9).  
However, the major disadvantage of the NOACs is the lack of specific antidotes that would 
reverse their action in a patient with major bleeding (1, 10, 11). Also, no reliable laboratory tests 
are available to monitor the effects of these agents (10, 11).Thus, there is some concern 
regarding the risk of major bleeding with these new agents, which on occasion can even be life 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
4 
 
threatening (1,10,11). No major study or systematic review focusing only on comparative 
bleeding risk with these drugs has been published.  At the same time there is no previous or 
ongoing, head-to-head trial among these new agents, although indirect comparisons provide 
some insights into some differences in safety endpoints (12).   
We performed a systematic review and meta-analysis of published randomized clinical trials to 
evaluate the risk of major bleeding with new oral anticoagulants.  
 
 
Methods  
 
We systematically searched the published literature for trials comparing any of the new oral 
anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban and darexaban) with conventionally 
used medications/anticoagulants among various indications for anticoagulation.  
 
Data Sources and Searches  
We electronically searched PubMed, Cochrane CENTRAL, EMBASE, EBSCO, Web of Science 
and CINAHL databases for English language, peer-reviewed publications of NOACs from 
January 2001 through October 31, 2013. Further details of the search strategy are mentioned  in 
the Online-only Data Supplement Appendix.  
   
Study Selection  
The included studies were randomized clinical trials; the trials evaluated any new oral 
anticoagulants including dabigatran, rivaroxaban, apixaban, edoxaban or darexaban; the 
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comparator was any active pharmacologic agents or placebo and major bleeding outcome was 
reported. We included studies with commonly evaluated indications for newer anticoagulants‟ 
use in randomized clinical trials: thromboprophylaxis after hip surgery, thromboprophylaxis after 
knee surgery, treatment of acute VTE or pulmonary embolism (PE), extended treatment of 
venous thromboembolism, prevention of embolism/stroke in atrial fibrillation (AF), acute 
coronary syndrome (ACS) and thromboprophylaxis in medically ill patients.  The PRISMA 
(Preferred Reporting Items for Systematic reviews and Meta-Analyses) statement for reporting 
systematic reviews and meta-analyses of RCTs (13) was used as a reference method for this 
study.  
 
Data Extraction and Quality Assessment 
Two authors (PS, SC) reviewed the trials, ensured that they met inclusion criteria and abstracted 
the data; disagreements were resolved by discussion with other authors.  Risk for bias was 
assessed by the procedures suggested by the Cochrane Handbook of Systematic Reviews (14).  
 
Data Synthesis and Analysis  
The outcome of interest was major bleeding events in the study group and the comparator group.  
For trials that evaluated 2 or more doses of NOACs, we used the outcome related to the approved 
total daily dose/closely related dose of the experimental drug for our analysis. For phase II trials 
we used the dose, which was subsequently tested in phase III trials, and when only phase II data 
was available, we chose the most frequently used dose of those drugs (for specific indications) in 
all trials with acceptable efficacy profile. ( Details in Online-only Data Supplement Appendix).   
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Statistical analysis   
We performed pooled comparisons between dabigatran, rivaroxaban, apixaban, edoxaban and 
darexaban versus comparators on safety analysis population. In this analysis, Review Manager 
Version 5.1 (The Nordic Cochrane Center, The Cochrane Collaboration, 2008, Copenhagen) was 
used. We calculated odds ratio (OR) estimates and associated 95% confidence intervals (CIs) for 
each of the oral anticoagulants and for each indication of use. We assessed the heterogeneity 
using the Cochran Q test and the Higgins I
2
 statistic . We calculated the total event rates 
calculated by summing up all events across all trials and dividing by the total number of patients 
across all trials. For our main analysis random effects models described by Der-Simonian and 
Laird was used. For studies using dissimilar agents in the control group, the random-effects 
model was applied. For sensitivity analysis, we used fixed effects model described by Mantel 
and Haenszel. We calculated prediction intervals for major bleeding using a random effect model 
(DerSimonian and Laird). Indirect comparisons between these drugs (with indication specific 
conventional drugs as a common comparator) were also done. We used Stata 11.2 (StataCorp 
LP, College Station, Texas) software for indirect comparisons [Bucher‟s method] (15).  Small 
study effects (publication bias) was assessed graphically by evaluating the standard error and the 
effect size in the funnel plots. 
 
 
Results 
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A total of 5742 reports were identified by our electronic database search (Figure 1). Finally, 50 
trials involving a total  155,537 patients in safety analysis groups met our inclusion criteria and 
were selected for the present analysis (Online-only Data Supplement Appendix ).   
 
Characteristics of included studies   
The included trials were conducted for different indications for anticoagulation therapy; 
thromboprophylaxis after hip surgery (12 studies), thromboprophylaxis after knee surgery (9 
studies), treatment of acute VTE/PE (8 studies), treatment of patients with ACS (6 studies), 
prevention of stroke/embolic events in patients with AF (10 studies), extended treatment of VTE 
(4 studies), and thromboprophylaxis in medically ill patients (2 studies). The BISTRO II trial 
included both hip and knee surgery patients, we used the published data for separate analysis 
(16). The numbers of included trials appraising rivaroxaban, apixaban, dabigatran, edoxaban and 
darexaban were eighteen, twelve, twelve, five and three respectively.  
Most of the studies used the International Society on Thrombosis and Hemostasis (ISTH) criteria 
in documenting major bleeding, though there were inter trial variation/modification in the 
definition (Online-only Data Supplement Appendix).   In the ACS trials, Thrombolysis In 
Myocardial Infarction (TIMI) major bleeding events were included in the analysis. In acute VTE 
studies patients received treatment for 3 or 12 months, and in "extended VTE treatment" studies 
patients received additional 6 to 12 months of treatment. For the studies with acutely ill medical 
patients, NOAC was given for 30-35 days versus LMWH for 6-14 days followed by placebo for 
the rest of the period.   
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Inter-rater reliability between the reviewers in the assessment of risk of bias was good with a 
kappa statistic of 0.85. A total of 33 studies showed low risk of bias, and among them 25 studies  
evaluated NOACs against active comparators.  
 
The pooled effect estimate according to Study Drug/ Comparator Drug (NOACs versus 
comparators)  
Pooled analysis of all NOACs together for all indications of anticoagulation showed, there was 
no significant difference between NOACs and pharmacologically active comparators for the risk 
of major bleeding [Odds ratio (OR) 0.93, 95% Confidence Interval (CI) 0.79- 1.09, I
2
=56%], 
2.4% with NOACs versus 2.7% with pharmacologically active comparators (Figure 2). 
Sensitivity analysis including trials with only low risk of bias also showed similar result (Online  
Supplement).  Newer agents caused statistically significant less major bleeding compared to 
vitamin K antagonists (OR 0.77, 95% CI 0.64- 0.91, I
2
=61%, p=0.003), 3.3% versus 3,9%. A 
similar result was found for pooled analysis with three available/approved NOACs (rivaroxaban, 
dabigatran, apixaban) (OR 0.76, 95% CI 0.63- 0.92, I
2
=67%, p=0.005), 3.6% versus 4.2% 
(Figure 3).   
Direct comparison analysis for individual NOACs showed, when considering each NOAC 
separately, there was on average no evidence of an effect of any of these relative to 
pharmacologically active agents; for rivaroxaban (OR 1.10, 95% CI 0.77- 1.58, I
2
=57%; 2.4% 
with rivaroxaban versus 2.3% with active agents), apixaban (OR 0.81, 95% CI 0.56- 1.119, 
I
2
=67%; 1.9% versus 2.5%) or dabigatran (OR 0.96, 95% CI 0.76- 1.20, I
2
=20%; 3.8 % versus 
4.0%) (Table 1). Similar findings with these three newer agents were also observed for separate 
analysis against vitamin K antagonists and low molecular weight heparin (LMWH) (Table 1).   
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
9 
 
Indirect comparisons between individual NOACs did not show any major differences between 
rivaroxaban, dabigatran, apixaban, edoxaban and darexaban for the risk of major bleeding 
(Online-only Data Supplement Appendix).  
 
 
The pooled effect estimate according to indications  
The pooled effect estimate for major bleeding complications with NOACs varied considerably 
across different indications of anticoagulation therapy.  
(a) Thromboprophylaxis after hip surgery (12 RCTs, 18627 patients): 
For the prevention of venous thromboembolism after hip surgery, there was a statistically 
significant higher risk of major bleeding with use of NOACs compared to LMWH (OR 1.43, 
95% CI 1.02 -1.99; I
2
=0%, p=0.04)  (Figure 4). Among 9262 patients there were 87 incidences 
(0.9%) of major bleeding with NOACs, whereas there were 61 incidences (0.6%) of major 
bleeding with LMWH among 9365 patients. When direct comparison analysis was done 
separately with pooled effects estimate of individual NOACs (rivaroxaban, dabigatran, apixaban, 
edoxaban and darexaban) versus LMWH, all the NOACs showed an increased trend towards 
major bleeding (Table2).  
(b) Thromboprophylaxis after Knee Surgery (9 RCTs, 15840 patients): 
For thromboprophylaxis after knee surgery, there was a trend towards less bleeding with NOACs 
but the results did not reach statistical significance (OR 0.88, 95% CI 0.55-1.39, I
2
=30%), 0.7% 
versus 0.9% (Figure 4). Apixaban individually caused significantly less bleeding in comparison 
to LMWH, when pooled analysis was done with phase III trials. But pooled effects of individual 
NOACs were not different from that of LMWH (Table 2).   
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(c )Extended Treatment of Venous Thromboembolism (4 RCTs, 7864 patients)  
Major bleeding with NOACs was not different compared to placebo (OR 1.87, 95% CI 0.19-
17.96, I
2
=61%), 0.3% versus 0.1% (Figure 4 and Table 2).  
 
(d) Acute Venous Thromboembolism/Pulmonary embolism (8 RCTs, 25161 patients) : 
In treatment of acute VTE/PE, NOACs caused significantly less bleeding  compared to 
conventional treatment (OR 0.63, 95% CI 0.44-0.90, I
2
=48%, p=0.01), 1.1% versus 1.7% (Figure 
5). Compared to VKA, the most robust evidence (from four RCTs) was found with rivaroxaban.    
(e ) Atrial Fibrillation (10 RCTs, 52539 patients)  
In patients with Atrial Fibrillation, bleeding risk with NOACs versus VKA/aspirin was not 
statistically different (OR 0.89, 95% CI 0.74-1.06), 4.5% versus 5.1%. There was considerable 
heterogeneity among the studies (I
2
=62%; p=0.01) (Figure 5). In our direct comparison analysis, 
pooled effects estimate of individual NOACs were not different from that of the comparator 
drugs (Table 2). 
 
(f ) Acute coronary syndrome (6 RCTs, 21107 patients) 
Uses of NOACs were associated with a high risk of major bleeding in patients with Acute 
Coronary Syndrome (OR 2.89, 95% CI 2.01-4.14, I
2
=-0%, p<0.001), 1.2% versus 0.4%, (Figure 
5). Individually, all three commonly-used NOACs dabigatran, rivaroxaban and apixaban caused 
more bleeding compared to placebo, results with rivaroxaban and apixaban were statistically 
significant (Table 2).  
 
(g) Thromboprophylaxis in Medically Ill Patients (2 RCTs, 14399 patients) 
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Newer agents caused  more major bleeding compared to LMWH/placebo after 30 days treatment 
period (OR 2.79, 95% CI 1.69-4.60, I
2
=0%, p<0.001), 0.8% versus 0.3%; however the CIs were 
wide (Figure 5 and Table 2). Separate analysis showed NOAC caused higher bleeding compared 
to initial LMWH therapy and also during “placebo comparison period”.  
Unlike the effects estimate according to the study drugs/comparator drugs, the majority of the 
results for indication-wise effects estimate showed insignificant heterogeneity.   
Small study effects 
We did not find any evidence of significant bias due to “small study effects” for our analyses 
with examination of funnel plots (Online supplement figure ).  
 
  
Discussion  
 
Our pooled analysis showed that, when compared against pharmacologically active drugs or 
placebo (in case of ACS), the risk of major bleeding overall was not significantly different with 
NOACs. Nonetheless, the newer agents may even cause lower major bleeding compared to 
VKA. Second, this meta-analysis identified important differences in major bleeding events with 
newer oral anticoagulants in different indications. Differences also exist with the type of surgical 
procedure; NOACs caused statistically significant higher rates of major bleeding compared to 
LMWH, when used after hip surgery. On the other hand there was a trend towards less bleeding 
with NOACs after knee surgery. For non-surgical indications, in treatment of acute VTE, 
NOACs showed consistently lower risk of bleeding, compared to VKA. In patients with atrial 
fibrillation and those undergoing extended treatment for VTE, NOACs and comparator drugs 
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showed no statistically significant differences in major bleeding. In patients with ACS and 
thromboprophylaxis in medically ill patients, NOACs caused more bleeding. For different 
indications of anticoagulation, no major difference in bleeding was found between any individual 
new agent (NOAC) versus comparator drugs in pooled effect estimates.  
 
Importantly, this study only analyzed data using approved doses of individual agents or 
commonly used doses in phase III trials. Thus, the results of our analysis are more likely to 
simulate real-life risk of major bleeding, assuming agents are used as in their respective clinical 
trials.   
 
The results of our meta-analysis perhaps reflect the complex nature of the coagulation cascade 
and multiple factors influencing it, as well as different dose regimens and concomitant 
comorbidities and drug therapies (10, 11, 17, 18).  As mentioned earlier, different dose regimens 
of NOAC have been used for different indications and NOACs have been evaluated against 
different comparators. This might explain some of the differences in risk of bleeding with NOAC 
in different indication of use. For instance, excess bleeding with NOACs in ACS might be 
related to co-interaction with anti-platelet therapy. Additionally, the comparison group in ACS 
trials was placebo (19, 20). However, the increased risk of major bleeding with newer agents 
might attenuate  their  ischemic benefits in patients with ACS (19).  
Higher rate of major bleeding in hip surgery but not in knee surgery may be related to the longer 
duration of NOAC therapy and higher baseline risk in subjects undergoing hip surgery (21, 22). 
Another point to consider is that comparator groups in most of the trials of hip surgery received 
40 mg daily LMWH (approved dose in Europe), while the majority of the comparator groups in 
knee surgery received 30 mg twice daily (i.e. total 60 mg daily; approved dose in North 
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America). Again, higher bleeding with NOACs in medically ill patients may be related to the 
baseline risks of the subjects, although „acute medically ill‟ represents a heterogeneous group of 
patient conditions (23, 24). 
 
A previous meta-analysis (20), reported that collectively, the risk of major bleeding 
complications was higher for rivaroxaban, and lower for apixaban and dabigatran; however, this 
analysis was affected by considerable heterogeneity. On the other hand, our pooled analysis did 
not show any significant difference with individual NOACs and pharmacologically active 
comparators. Our indirect comparison analysis also did not show any major differences between 
the individual NOAC; for all indications together and also for separate analysis for individual 
indications. When we pooled the data according to the indications of anticoagulation (instead of 
according to individual drugs), focusing on approved doses of the individual drugs available, 
most of our findings showed no marked heterogeneity. Thus, when considering the bleeding risk 
of NOACs, examining the specific indication for anticoagulation may be more relevant than 
looking for individual drug effects among all indications.  
 
A recent meta-analysis did not find any statistically significant interaction of the type of surgery 
(total hip or knee replacement) for clinically relevant bleeding (25).  Another meta-analysis 
pooled the data of both knee and hip surgery and reported that use of factor Xa inhibitors 
increased the risk of major bleeding (26). On the contrary, in our analysis, NOACs were 
associated with significantly higher risk of bleeding with hip surgery, but not in knee surgery. 
Thus, the risk of bleeding may possibly be more related to type of surgery, baseline risk of 
subjects, or comparators than type of NOACs used. Despite recent reports suggested the 
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possibility of higher bleeding with newer agents (1, 20), our findings that major bleeding is 
actually lower with NOACs may justify use of NOACs in patients with high risk of bleeding 
with VKA. Of note, we did not find any specific advantage of any individual NOACs against 
VKA.  
 
Bleeding risk is the major limitation with new anticoagulant therapy, as there is no reliable 
reversal agent. At the same time the NOACs have definite advantage in term of efficacy and 
convenience in long term use over conventional anticoagulants like VKA/heparin (1,10, 11, 27). 
In this situation prediction of bleeding according to the indication of anticoagulation and careful 
patient as well as specific newer agent selection is the only acceptable option to optimize the 
bleeding risk.  However, inter-agent comparisons of this kind can only be considered to be 
hypothesis generating and provide the basis for large head to head randomized controlled trials.   
 
Limitations  
We recognize differences in study population, protocol, intervention and duration of follow-up 
across the included trials. Widened confidence intervals for few agents and indications make 
interpretation difficult, especially in cases of edoxaban and darexaban. Our results are estimates 
of average effects, and  a degree of unexplained statistical heterogeneity around these averages is 
present. Definitions of major bleeding varied considerably in the studies, which was very 
difficult to adjust in the pooled analysis.  All included studies reported major bleeding as a 
composite outcome, and components of the composite outcome ranging from severe intracranial 
bleeding to comparatively less important outcomes such as decrease in hemoglobin level of 2 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
15 
 
g/dl, which make interpretation of the combined results challenging. Effects of older age and 
impaired renal function on bleeding risks could not be pooled due to non-availability of data.  
 
Conclusion   
NOACs may be related to higher risk of bleeding in hip surgery, acute coronary syndrome and 
thromboprophylaxis in medically ill patients, but causes less bleeding in patients with acute 
venous thromboembolism (VTE) or pulmonary embolism (PE). In patients with atrial 
fibrillation, knee surgery and extended treatment of venous thromboembolism, NOACs may not 
necessarily be associated with increased bleeding risk when used in approved doses. Collectively 
and individually the NOACs may cause equal or even less major bleeding when compared to 
vitamin K antagonists.  
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 Figure Legends   
Figure 1: Search strategy and study selection as per PRISMA checklist.    
Figure 2:  Forest plot comparing all new oral anticoagulants versus pharmacologically active agents for 
risk of major bleeding  
Figure 3:  Forest plot for major bleeding comparing three approved/available new oral anticoagulants 
(rivaroxaban, dabigatran and apixaban) versus vitamin K antagonists.  
Figure 4: Risk of major bleeding with NOACs versus comparators, for thromboprophylaxis after hip 
surgery (A), for thromboprophylaxis after knee surgery (B), and for extended treatment of venous 
thromboembolism(C) 
Figure 5: Risk of major bleeding with NOACs versus comparators, for treatment of acute VTE/PE (A), 
for Atrial Fibrillation (B), for Acute Coronary Syndrome (C) and for thromboprophylaxis in medically ill 
patients(D)  
Table 1: Analysis of pool effect estimates of NOACs versus comparators, according to study and 
comparator drugs.  
Table 2: Direct comparison analysis of pool effect estimates of individual NOACs versus comparator 
drugs, according to different indications.   
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Table 1: Analysis of pool effect estimates of NOACs versus comparators, according to study and 
comparator drugs.  
 Study drug-incidence/total 
Comparators-incidence/total 
Odds Ratio  (95% CI) No of 
Study  
All NOACs vs active 
comparators 
1544/64716 
1733/64706  
0.93 [0.79, 1.09], I
2
=56% 
 
42 studies  
 
All NOACs vs active 
comparators (phase III 
trials) 
1512/62126 
1710/62096 
0.90 [0.76, 1.07]. I
2
=69% 24 studies 
All NOACs vs Vitamin K 
antagonist 
1339/40364 
1580/40192 
0.77 [0.64, 0.91], I
2
=61% 19 studies 
 
All NOACs vs LMWH 
 
205/24352 
153/24514 
1.32 [0.98, 1.78], I
2
=34% 
 
23studies 
 
3 Available NOACs vs 
active comparator 
1485/59786 
1662/59756 
 0.94 [0.79, 1.12], I2=61% 
 
35 Studies  
 
3 Available NOACs vs 
Vitamin K antagonist 
1283/35801 
1511/35616  
0.76 [0.63, 0.92]I
2
=67% 
 
15 studies 
 
3 Available NOACs vs 
LMWH 
202/23985 
151/24140 
1.32 [0.96, 1.81], I
2
=40% 
 
20 studies 
 
3 Available NOACs vs 
LMWH(Excluding 
MAGELLAN &ADOPT) 
144/16804 
130/16922 
 
1.12 [0.84, 1.51], I
2
=19% 
 
18 studies 
 
Dabigatran  vs active 
comparators  
500/13031 
526/12894 
0.96 [0.76, 1.20], I
2
=20 
 
10 studies  
 
Dabigatran vs Vitamin K 
antagonist  
432/8946 
470/8783  
0.83 [0.62, 1.12], I
2
=33% 
 
4 studies  
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Dabigatran vs LMWH 
 
68/4085 
56/4111 
1.23 [0.86, 1.77], I
2
=0% 
 
5 studies 
 
Rivaroxaban  vs active 
comparators 
537/22725 
525/22857 
1.10 [0.77, 1.58], I
2
=57% 
 
15 studies 
 
Rivaroxaban vs Vitamin 
K antagonist 
464/12084 
490/12100  
0.79 [0.55, 1.13], I
2
=54% 
 
6 studies 
Rivaroxaban vs LMWH 
 
73/10641 
35/10757 
2.05 [1.29, 3.24] , I
2
=6% 
 
9 studies 
 
Rivaroxaban vs LMWH 
(excluding MAGELLAN 
trial) 
30/6644 
20/6756 
1.56 [0.86, 2.83], I
2
=0% 
 
8 studies  
 
Apixaban vs all active 
comparators 
448/24030 
611/24005 
0.81 [0.56, 1.19], I
2
=67% 
 
10 studies  
 
Apixaban vs Vitamin K 
antagonist  
387/14771 
551/14733 
0.66 [0.40, 1.09], I
2
=70% 
 
5 studies 
 
Apixaban vs LMWH 61/9259 
60/9272 
1.08 [0.54, 2.12], I
2
=63% 
 
5 studies 
Apixaban vs LMWH 
(excluding ADOPT trial) 
46/6075 
54/6055 
0.84 [0.43, 1.62], I
2
=53% 
 
4 studies 
 
 
Bold signifies statistically significant result  
ADOPT=Apixaban Dosing to Optimize Protection from Thrombosis trial;  CI =Confidence Interval; 
LMWH=Low molecular weight heparin.  
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Table 2: Direct comparison analysis of pool effect estimates of individual NOACs versus 
comparator drugs, according to different indications 
Hip Surgery Odds Ratio  
(95% CI) 
Treatment of acute  
VTE/PE 
Odds Ratio  
(95% CI) 
Dabigatran vs. comparator 1.49 [0.96, 2.34], 
I
2
=0%, 3 studies 
Dabigatran vs. comparator 0.82 [0.45, 1.50] , 
I
2
=NA,  1study 
Rivaroxaban vs. comparator 1.71 [0.67, 4.39] , 
I
2
=0%, 5 studies 
Rivaroxaban vs. comparator 0.57 [0.39, 0.83] , 
I
2
=0%, 4 studies 
Apixaban vs. comparator 1.22 [0.65, 2.28] , 
I
2
=NA,  1 study  
Apixaban vs. comparator 2.57 [1.03, 6.37] , 
I
2
=0%, 1 study 
Edoxaban vs. comparator 3.05 [0.12,75.47] , 
I
2
=NA, 1 study 
Acute Coronary Syndrome 
Darexaban vs. comparator 0.21 [0.01, 4.41] , 
I
2
=NA,  2 studies 
Dabigatran vs. comparator 1.07 [0.07, 17.16] 
, I
2
=NA,  1 study 
Knee Surgery Rivaroxaban vs. comparator 3.45 [2.07, 5.76] , 
I
2
=NA,  1 study 
Dabigatran vs. comparator 0.85 [0.45, 1.58] , 
I
2
=0%, 3 studies 
Apixaban vs. comparator 2.58[1.53, 4.35] , 
I
2
=0%, 2 studies 
Rivaroxaban vs. comparator 1.40 [0.55, 3.55] , 
I
2
=23%,  3studies 
Darexaban vs. comparator 0.69 [0.03, 17.08] 
, I
2
=NA,  1 study 
Apixaban vs. comparator 0.69 [0.30, 1.61] , Atrial Fibrillation  
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I
2
=46%,  3studies 
Extended treatment of VTE Dabigatran vs. comparator 0.94 [0.81, 1.08] , 
I
2
=NA, 2 studies 
Dabigatran vs. comparator 0.96 [0.13,6.97] , 
I
2
=51%, 2 studies 
Rivaroxaban vs. comparator 1.02 [0.88, 1.17] , 
I
2
=0%, 2 studies 
Apixaban vs. comparator 0.37[0.08,1.67], 
I
2
=NA,  1 study 
Apixaban vs. comparator 0.82 [0.55, 1.24] , 
I
2
=55%,  3studies 
Acutely  Ill Medical Patients   Edoxaban vs. comparator 0.25 [0.03, 2.29] , 
I
2
=0%, 3 studies 
Rivaroxaban vs. comparator 2.89[1.60,5.21] , 
I
2
=NA,  1 study 
  
Apixaban vs. comparator  2.53[0.98,6.54] , 
I
2
=NA,  1 study 
  
 
Bold signifies statistically significant result  
CI =Confidence Interval; NA=not applicable; PE= Pulmonary embolism; VTE= Venous 
Thromboembolism.   
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Fig. 1. Search strategy and study selection as per PRISMA checklist.   
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
25 
 
Fig. 2 
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Fig. 3 
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Fig. 4 
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Fig. 5 
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Highlights 
 We performed a meta-analysis to evaluate the risk of major bleeding with the use of New 
Oral Anticoagulants (NOACs).  
 Risk of major bleeding with new oral anticoagulants varies with their indication for use.  
 NOAC may increase the risk of major bleeding after hip surgery, acute coronary 
syndrome and acute medically ill patients; but may be associated with less bleeding in 
treatment of acute venous thromboembolism or pulmonary embolism. 
